Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
- 1 November 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 104 (9), 2926-2932
- https://doi.org/10.1182/blood-2004-03-1134